Treatment of early-stage Hodgkin lymphoma
Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD followed by 20 Gy involved-field radiation therapy (IF-RT) are sufficient and result in more than 90% of patients being cured.
Source: Seminars in Hematology - Category: Hematology Authors: Andreas Engert, John Raemaekers Source Type: research
More News: Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | Hodgkin's Disease | Lymphoma | Radiation Therapy | Study